| Bioactivity | DHODH-IN-12 (Compound 12b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a pKa of 5.07[1]. |
| Target | pKa: 5.07 (DHODH) |
| Invitro | Designed a compound structurally related to Leflunomide, containing the furazan ring (Compound 12a), is designed. Compound 12a undergo ring 4 scission under physiological pH conditions to afford the corresponding cyano-oximes DHODH-IN-12 (Compound 12b). DHODH-IN-12 has been assayed as a DHODH inhibitor; its low potency is probably due to the unfavourable stereochemistry of the oxime substructure[1]. |
| Name | DHODH-IN-12 |
| CAS | 1263303-93-0 |
| Formula | C10H9N3O2 |
| Molar Mass | 203.20 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Giorgis M, et al. 1,2,5-Oxadiazole analogues of leflunomide and related compounds. Eur J Med Chem. 2011 Jan;46(1):383-92. |
DHODH-IN-12
CAS: 1263303-93-0 F: C10H9N3O2 W: 203.20
DHODH-IN-12 (Compound 12b) is a Leflunomide derivative and a weak dihydroorotate dehydrogenase (DHODH) inhibitor with a
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.